Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their ...

A look at the shareholders of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are private equity firms with 46 ...

Reneo Pharmaceuticals Inc (NASDAQ:RPHM) anticipates pivotal STRIDE study topline data in December 2023. Q3 2023 saw a net loss of $19.2 million, a deeper loss compared to Q3 2022's $13.0 million.

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Reneo Pharmaceuticals is developing mitochondrial disease therapies, with its lead program being mavodelpar or REN001. Mavodelpar has shown promising results in increasing fatty acid oxidation and ...

Reneo Pharmaceuticals RPHM, a clinical-stage company, announced the failure of the mid-stage pivotal STRIDE study of its investigational candidate, mavodelpar (REN001), to treat primary mitochondrial ...

Reneo Pharmaceuticals, developing therapies for rare genetic mitochondrial diseases, has been added to the Russell 3000 index and raised around $55 million through a recent public offering. RPHM's ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) and OnKure, Inc. is fair to Reneo ...